Hong Kong-listed biopharmaceutical firm 3SBio Inc. reported the repurchase of 337,500 ordinary shares on 14 October 2026, paying a uniform price of HK$14.40 per share. The on-market transaction totalled HK$4.86 million and all repurchased shares have been transferred to treasury stock.
Following the buyback, the company’s issued share capital (excluding treasury shares) declined from 2.513545 billion to 2.513208 billion, a marginal reduction of 0.01%. Treasury shares increased to 25.11 million, bringing total issued shares (including treasury stock) to 2.538321 billion.
The transaction was conducted under the repurchase mandate approved by shareholders on 25 June 2026, which authorises 3SBio to acquire up to 253.71 million shares. To date, the company has repurchased 24.10 million shares under this mandate, equivalent to 0.95% of the issued share base as at the mandate date.
In line with Hong Kong Stock Exchange rules, 3SBio is subject to a 30-day moratorium—through 13 November 2026—on issuing new shares or disposing of treasury shares following the repurchase. The company confirmed that the transaction complied with all relevant Main Board requirements and its previously issued Explanatory Statement dated 3 June 2026.
Comments